139 filings
Page 2 of 7
8-K
62ywi
23 Mar 23
Departure of Directors or Certain Officers
4:30pm
8-K
mlu7q ztnu4gmk86b8
22 Mar 23
Other Events
5:00pm
8-K
n8nateerkmljnmwe9u
20 Mar 23
MyMD Pharmaceuticals® and Charles River Present Positive Data for Next Generation, Oral TNF-α Inhibitor MYMD-1® in Rheumatoid Arthritis
9:15am
8-K
nd6r8w4n0v2unnrhb
8 Mar 23
MyMD Joins LOT Network in Effort to Protect Company and Shareholders from Patent Trolls
8:40am
8-K
463cuf xbm6p7
2 Mar 23
MyMD Announces U.S. Drug Enforcement Administration (DEA) Determines
8:45am
8-K
nnfn2g1zy903mm
28 Feb 23
Regulation FD Disclosure
4:15pm
8-K
xsxhdc0dv4mai5wlf
23 Feb 23
Entry into a Material Definitive Agreement
3:24pm
8-K
co2ebrrd
21 Feb 23
MyMD Announces $15 Million Offering with Existing Investors
9:00am
8-K
8mt0p2ct0y320w
3 Feb 23
Departure of Directors or Certain Officers
4:15pm
8-K
ps2pgftuvkbdipk
14 Dec 22
Submission of Matters to a Vote of Security Holders
5:00pm
8-K
ivoxyx86z tp
8 Dec 22
MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022
4:15pm
8-K
3l86o6s59
18 Nov 22
MyMD Pharmaceuticals® Announces Upcoming Presentation of Late-Breaking Data for MYMD-1® at the 2022 British Society for Immunology (BSI) Congress
4:30pm
8-K
67g7m7v n5
14 Nov 22
MyMD Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1® in Peer-Reviewed Journal Data Research
8:32am
8-K
7yoi8zeqlijdog70v1
20 Sep 22
Efficacy data anticipated in Q4 of 2022
8:00am
8-K
bwz5xyf
31 Aug 22
Mymd Pharmaceuticals Receives Grant from European
8:00am
8-K
jm0ja3 eph5
17 Aug 22
Entry into a Material Definitive Agreement
5:16pm
8-K
zh25hicwb 048j6s18g
3 Aug 22
Regulation FD Disclosure
4:30pm
8-K
yqe02wyu vy5f
26 Jul 22
Regulation FD Disclosure
4:30pm
8-K
czufzxg4w
12 Jul 22
Bascom Palmer Eye Institute ranked the #1 eye hospital in the United States for 20 years in a row by U.S. News & World Report
4:05pm
8-K
50m 78wuz9
21 Jun 22
Regulation FD Disclosure
10:30am